Menu

Merck & Company

NYSE: MRK

Merck is a global pharmaceutical company that develops and sells prescription medicines, vaccines and animal health products. Its pharmaceutical business focuses on oncology, infectious diseases, cardiovascular conditions and other major therapeutic areas. Keytruda, its leading cancer immunotherapy, is a major revenue driver, while Gardasil is another important vaccine franchise. Its Animal Health business provides medicines, vaccines and healthcare solutions for livestock and companion animals.

Sector
Health Technology
Industry
Pharmaceuticals: Major
Employees
75,000
Founded
1891

The forecast figures are tipranks’s, read on 2026-11-16 and linked below.
The company facts and financials are CNN Business’s, read on 2026-11-16 and linked below.

Merck & Company forecast

The forecast in short

tipranks records 22 analyst ratings on Merck & Company and summarises them as “Moderate Buy”. Their average 12-month price target is USD 162.14 (9.73% Upside). Its tipranks score is 8 out of 10 — Outperform. These are tipranks’s figures as read on 2026-11-16, not CariBroker’s own view, and nothing here is advice to buy or sell.

Market cap

USD 339.66 B

≈ RM 1.39 T

Share price

USD 137.78

≈ RM 563.60 · 18 Nov close

#40World ranking

tipranks score

Outperform

8

Analyst ratings

Moderate Buy

  • Buy1568%
  • Hold732%
  • Sell00%

tipranks’s own summary of the 22 ratings above.

12 months price forecast

USD 162.14 9.73% Upside

USD 97.31USD 127.38USD 157.45USD 187.52Past 12 months12 months forecastHighUSD 180AverageUSD 162.14LowUSD 1052025-112026-11

As tipranks publishes it. CariBroker has not recalculated any of it.

Financials

Q3 earnings, quarter ending Sep 29, 2026

MeasureQ3 20261-year change
Total revenue18.12B11.02% up
Net income5.07B70.94% up
Earnings per share2.0411.74% down
Net profit margin27.95%16.99% down
Free cash flow5.52B202.52% up
Debt-to-equity ratio1.2050.12% up

Revenue and net income, last 4 quarters

-$5.0B$0.0$5.0B$10.0B$15.0B$20.0BQ4 2025Q1 2026Q2 2026Q3 2026

Total revenueNet income

Analyst profiles: who made each call, and when

AnalystFromPositionTarget priceDated
Carter GouldCantor FitzgeraldHoldUSD 1552026-11-11
Louise ChenScotiabankBuyUSD 1802026-11-10
Trung HuynhRBC CapitalHoldUSD 1402026-11-05
Elmar KrausDZ BANK AGHoldUSD 1532026-11-03
Daina GrayboschLeerink PartnersBuyUSD 1622026-11-02
Show all 27
AnalystFromPositionTarget priceDated
Ilya ZubkovFreedom Capital MarketsHoldUSD 1402026-11-02
Jason GerberryBank of America SecuritiesBuyUSD 1652026-10-30
Evan SeigermanBMO CapitalBuyUSD 1702026-10-30
Terence FlynnMorgan StanleyBuyUSD 1742026-10-30
Chris SchottJ.P. MorganBuyUSD 1752026-10-30
Vamil DivanGuggenheimBuyUSD 1712026-10-29
Emily FieldBarclaysBuyUSD 1802026-10-28
Geoff MeachamCitiHoldUSD 1452026-10-27
Mohit BansalWells FargoBuyUSD 1652026-10-26
Courtney BreenBernsteinHoldUSD 1052026-10-25
Michael YeeUBSBuyUSD 1752026-10-24
Asad HaiderGoldman SachsBuyUSD 1552026-10-22
Steve ScalaTD CowenHoldUSD 1552026-09-22
Nico ChenDBSBuyUSD 1802026-09-11
Rajesh KumarHSBCBuyUSD 1722026-09-10
Alexandria HammondWolfe ResearchBuyUSD 1802026-08-25
Jasper HellwegArgus ResearchBuyUSD 1702026-08-24
Luisa HectorBerenberg BankHoldUSD 1272026-08-05
Unknown AnalystJefferiesBuyUSD 1382026-05-19
Hans EngelErste GroupHoldN/A2026-05-05
Natalya DaviesRothschild & Co RedburnBuyUSD 1792026-04-17
James ShinDeutsche BankBuyUSD 1502026-02-13

Investment strengths

Diversified product growth

Revenue growth is supported by multiple therapeutic and animal-health franchises rather than a single product. Continued contributions from new products, oncology and animal health broaden the earnings base and provide durable commercial momentum over the next several quarters.

Pipeline strength

Late-stage clinical and regulatory progress strengthens Merck’s ability to replenish growth as mature products age. Positive results across oncology, vaccines and pulmonary hypertension diversify future launch opportunities and improve the durability of the portfolio.

Strong cash generation

Substantial operating and free cash flow gives Merck capacity to fund research, launches, capital needs, dividends and business development internally. Strong cash conversion supports financial resilience even while recent free-cash-flow growth has moderated.

People also ask

What is the 12-month price target for Merck & Company (MRK)?

tipranks publishes an average 12-month price target of USD 162.14 (9.73% Upside), as read on 2026-11-16. The highest target is USD 180 and the lowest is USD 105. A price target is an analyst’s estimate of where a share might trade, not a promise, and CariBroker gives no investment advice.

See tipranks’s own page ↗

How many analysts cover Merck & Company (MRK)?

tipranks records 22 analyst ratings: 15 buy, 7 hold and 0 sell, which it summarises as “Moderate Buy”, as read on 2026-11-16.

See tipranks’s own page ↗

What is the tipranks score for Merck & Company (MRK)?

tipranks scores it 8 out of 10 and calls that “Outperform”, as read on 2026-11-16. The score is tipranks’s, not CariBroker’s, and CariBroker does not rate listed shares.

See tipranks’s own page ↗

Is this CariBroker’s own forecast for Merck & Company?

No. Every figure on this page is published by tipranks, copied on 2026-11-16 with a link to the original, and not recalculated. CariBroker checks financial companies in Malaysia against the public registers; it makes no forecast of its own and holds no licence to advise on securities.

See tipranks’s own page ↗

Disclaimer

CariBroker provides information only and does not provide investment, financial or legal advice.

All investment ideas

Check another company

Search every bank, broker and alert list in one place